Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NICE backs new use for Bayer’s Eylea

NICE backs new use for Bayer’s Eylea Will go up against Novartis’ Lucentis in treatment of macular oedema in UK. ... Eylea is already available on the NHS to treat wet age-related macular degeneratio n (AMD), a condition for which Lucentis is also approved.

Interview: Beate Wieseler, IQWIG

Interview: Beate Wieseler, IQWIG effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

Roche signs $1bn-plus cancer deal with Molecular Partners

Roche signs $1bn-plus cancer deal with Molecular Partners time to re-treatment and with signs that inflammation in the eye could be worse than with rival treatment Lucentis (ranibizumab) from Roche.

NICE backs two eye treatments

NICE backs two eye treatments NICE, which provides guidance on the cost-effectiveness of treatments for NHS use, published final guidance backing both a new indication for Novartis' eye drug Lucentis (ranibizumab) and Alimera Sciences' intravitreal ... As per the Lucentis guidance,

Scotland first in UK to back Pfizer's Inlyta

Scotland first in UK to back Pfizer's Inlyta month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research